Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemigliptin on Metabolic Endotoxemia in T2D
NCT02186080Completed
- Sponsor
- Seoul National University Hospital
- Start
- Jul 2014
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Gemigliptin with Placebo (2 arms). Primary endpoint: Difference between baseline and peak serum LPS. Started Jul 2014; status: completed.
02
Drugs
gemigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02186080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02186080.